Abstract:Zr-metal-organic frameworks (Zr-MOFs) have received increasing interest in serving as the signal marker to develop sandwich-structured aptasensors for detection of exosomes. However, Zr4+ ions of the Zr-MOFs can interact with...
“…CD63-specific aptamers were immobilized on the surface of magnetic Fe 3 O 4 particles coated with polydopamine (PDA), along with UiO-66-NH 2 for exosome capture. As a result, the prepared aptasensors exhibited enhanced sensitivity with a detection limit of 86.2 particles/µL and demonstrated high selectivity towards exosomes originating from various sources, including the MCF-7 cell line and HeLa cell line [ 192 ]. Figure 4.…”
Section: Nanoarchitectonics Based Electrochemical Biosensing For Impr...mentioning
Exosomes, a type of extracellular vesicles, have attracted considerable attention due to their ability to provide valuable insights into the pathophysiological microenvironment of the cells from which they originate. This characteristic implicates their potential use as diagnostic disease biomarkers clinically, including cancer, infectious diseases, neurodegenerative disorders, and cardiovascular diseases. Aptasensors, which are electrochemical aptamers based biosensing devices, have emerged as a new class of powerful detection technology to conventional methods like ELISA and Western analysis, primarily because of their capability for high-performance bioanalysis. This review covers the current research landscape on the detection of exosomes utilizing nanoarchitectonics strategy for the development of electrochemical aptasensors. Strategies involving signal amplification and biofouling prevention are discussed, with an emphasis on nanoarchitectonics-based bio-interfaces, showcasing their potential to enhance sensitivity and selectivity through optimal conduction and mass transport properties. The ongoing challenges to broaden the clinical applications of these biosensors are also highlighted.
“…CD63-specific aptamers were immobilized on the surface of magnetic Fe 3 O 4 particles coated with polydopamine (PDA), along with UiO-66-NH 2 for exosome capture. As a result, the prepared aptasensors exhibited enhanced sensitivity with a detection limit of 86.2 particles/µL and demonstrated high selectivity towards exosomes originating from various sources, including the MCF-7 cell line and HeLa cell line [ 192 ]. Figure 4.…”
Section: Nanoarchitectonics Based Electrochemical Biosensing For Impr...mentioning
Exosomes, a type of extracellular vesicles, have attracted considerable attention due to their ability to provide valuable insights into the pathophysiological microenvironment of the cells from which they originate. This characteristic implicates their potential use as diagnostic disease biomarkers clinically, including cancer, infectious diseases, neurodegenerative disorders, and cardiovascular diseases. Aptasensors, which are electrochemical aptamers based biosensing devices, have emerged as a new class of powerful detection technology to conventional methods like ELISA and Western analysis, primarily because of their capability for high-performance bioanalysis. This review covers the current research landscape on the detection of exosomes utilizing nanoarchitectonics strategy for the development of electrochemical aptasensors. Strategies involving signal amplification and biofouling prevention are discussed, with an emphasis on nanoarchitectonics-based bio-interfaces, showcasing their potential to enhance sensitivity and selectivity through optimal conduction and mass transport properties. The ongoing challenges to broaden the clinical applications of these biosensors are also highlighted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
